MOSCOVITCH-LOPATIN M, CROMWICK AM, PUMA MD, ROSENBERG M, MILDER FL; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 613 (abstract no. 774).
Implemed, Watertown, MA.
Up to 40% of all patients with indwelling urinary catheters develop catheter associated urinary tract infections (CAUTI), many of which will involve resistant strains of bacteria. The availability of a Foley catheter with extended, broad-spectrum antimicrobial effectiveness is of particular interest. OLIGON[TM], an antimicrobial technology based on the prolonged, oligodynamic iontophoretic (OI) release of silver ions (Ag[+]), currently used in vascular access devices, was investigated in vitro for its antimicrobial effectiveness in simulated long-term urethral catheterization. The antimicrobial effectiveness of Oligon[TM]-coated silicone Foley catheters was compared in vitro to that of metallic silver/hydrogel coated- Bardex[[TM]], I.C. Foley latex catheters in a turbidity assay. Samples of catheters were transferred daily into fresh synthetic human urine supplemented with 5%Tryptic Soy Broth and inoculated with 10[3]-10[4] CFU/mL Escherichia coli. Turbidity, signifying bacterial growth to >/= 10[6 ]CFU/ml, was assessed spectrophotometrically after 24 hours incubation and the results compared to controls. Oligon segments were found to maintain the cultures clear for more than 84 days, while Bardex[[TM]], I.C. cultures became as turbid as the inoculated control after approximately 6 days. The Ag[+] released by Oligon, as measured by atomic absorption spectroscopy, was greater than the MIC values of AgNO[3] in synthetic urine (pH 5.5 and 7.2). Scanning electron micrographs of the catheter segments after 84 days of testing showed no colonization of the Oligon segments, while the Bardex[[TM]], I.C. segments were colonized. In addition, the OI Ag[+] demonstrated effectivity against a broad range of microorganisms, including Methicillin Resistant Staphylococcus aureus and Vancomycin Resistant Enterococcus faecalis. These results indicate Oligon[TM] shows promise in reducing the incidence of CAUTI, hence reducing the incidence of nosocomial infections. Clinical studies are now in progress to determine the effectiveness of Oligon[TM] in reducing the risk of CAUTI.
Publication Types:
Keywords:
- Anti-Infective Agents
- Bacteria
- Coloring Agents
- Cross Infection
- Humans
- Hydrogel
- In Vitro
- Silicones
- Silver
- Silver Sulfadiazine
- Staining and Labeling
- Staphylococcus aureus
- Urinary Catheterization
- Urinary Tract Infections
Other ID:
UI: 102246216
From Meeting Abstracts